Literature DB >> 12902018

Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study.

S Rahman1, J Zhang, W A Corrigall.   

Abstract

The objectives of the present study were to examine the effects of acute and chronic nicotine on dopamine (DA) release in the ventral tegmental area (VTA) of Long-Evans rats using in vivo microdialysis. Systemic application of acute nicotine (0.1-0.3 mg/kg, s.c.) significantly increased (145% of baseline) DA release in the VTA. Chronic exposure to nicotine (0.3 mg/kg, s.c.) for 5 days followed by a challenge dose of nicotine (0.3 mg/kg, s.c.) also produced significant enhancement (136% of baseline) of DA release in the VTA. The results suggest that both acute and chronic nicotine treatment exert stimulatory effects on somatodendritic DA release in the VTA. The enhancement of DA release to subsequent challenge nicotine may be susceptible to mild desensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902018     DOI: 10.1016/s0304-3940(03)00723-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  Phasic D1 and tonic D2 dopamine receptor signaling double dissociate the motivational effects of acute nicotine and chronic nicotine withdrawal.

Authors:  Taryn E Grieder; Olivier George; Huibing Tan; Susan R George; Bernard Le Foll; Steven R Laviolette; Derek van der Kooy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Methamphetamine produces bidirectional, concentration-dependent effects on dopamine neuron excitability and dopamine-mediated synaptic currents.

Authors:  Sarah Y Branch; Michael J Beckstead
Journal:  J Neurophysiol       Date:  2012-05-16       Impact factor: 2.714

4.  A double-blind placebo controlled experimental study of nicotine: I--effects on incentive motivation.

Authors:  Lynne Dawkins; Jane H Powell; Robert West; John Powell; Alan Pickering
Journal:  Psychopharmacology (Berl)       Date:  2006-10-18       Impact factor: 4.530

5.  Smoking, melanization, and cryptococcosis: is there a connection?

Authors:  Z U Khan
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Nicotine modulates alcohol-seeking and relapse by alcohol-preferring (P) rats in a time-dependent manner.

Authors:  Sheketha R Hauser; Bruk Getachew; Scott M Oster; Ronnie Dhaher; Zheng-Ming Ding; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2011-06-20       Impact factor: 3.455

7.  Selective breeding for high alcohol preference increases the sensitivity of the posterior VTA to the reinforcing effects of nicotine.

Authors:  Sheketha R Hauser; Amy L Bracken; Gerald A Deehan; Jamie E Toalston; Zheng-Ming Ding; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Addict Biol       Date:  2013-03-18       Impact factor: 4.280

8.  Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function.

Authors:  S Singer; S Rossi; S Verzosa; A Hashim; R Lonow; T Cooper; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

9.  Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine preexposure.

Authors:  S Rahman; J Zhang; W A Corrigall
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

10.  Tris-azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Guangrong Zheng; Sangeetha P Sumithran; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.